Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management

BACKGROUND: Vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitors (TKIs) are widely used in cancer treatment and burdened by cardiovascular toxicity. The majority of data come from clinical trials, thus in selected populations. The aim of our study is to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallerio, P., Orenti, A., Tosi, F., Maistrello, M., Palazzini, M., Cingarlini, S., Colombo, P., Bertuzzi, M., Spina, F., Amatu, A., Lombardo, R., Prata, I., Scaglione, F., Vighi, G.D., Severgnini, B., Siena, S., Giannattasio, C., Boracchi, P., Sartore-Bianchi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685997/
https://www.ncbi.nlm.nih.gov/pubmed/34920290
http://dx.doi.org/10.1016/j.esmoop.2021.100338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685997/
https://www.ncbi.nlm.nih.gov/pubmed/34920290
http://dx.doi.org/10.1016/j.esmoop.2021.100338

Ejemplares similares